ArticleNanotechnology, science and applications2025
Tailoring CdO-CuO-ZnO Mixed Metal Oxide Nanocomposites for Anticancer Activity via Co-Precipitation Method.
Article in Nanotechnology, science and applications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The use of metal oxide nanoparticles as anticancer agents is of great interest due to their unique properties that allow targeted delivery at low concentrations with minimal toxicity to healthy cells. Methods: In this work, CdO-CuO-ZnO mixed metal oxide nanocomposites were synthesized by the co-precipitation method, and their structural and optical properties, along with their anticancer activity, were investigated. The samples were characterized by X-ray diffraction (XRD), total reflection X-ray fluorescence (TXRF), transmission electron microscopy (TEM), selected area electron diffraction (SAED), UV-Vis spectroscopy, electrometer/high resistance material, and vibrating sample magnetometers (VSM). Results: X-ray diffraction (XRD) measurements showed that CdO exhibits a cubic structure, CuO possesses a monoclinic structure, ZnO displays a hexagonal structure, and the mixture showed peaks corresponding to all three oxides. TEM images revealed that the prepared nanoparticles have quasi-spherical shapes. Anticancer studies confirmed that the CdO-CuO-ZnO nanocomposite demonstrates excellent cytotoxicity, with moderate activity against human colon (Caco-2) and lung (A549) cancer cell lines, exhibiting IC50 values of 10.57 μg/mL and 6.61 μg/mL, respectively. Conclusion: Our study shows that the prepared CdO-CuO-ZnO nanocomposite has massive potential in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.